JPRN-UMIN000018252已完成未知
Evaluation of safety and tolerability of mesenchymal stem cell mobilization factor KOI2 (Phase 1 study ) - Evaluation of safety and tolerability of mesenchymal stem cell mobilization factor KOI2 (Phase 1 study )
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 入组人数
- 48
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 40years-old（—）
- 性别
- Male
入选标准
- 未提供
排除标准
- •1) A subject who has liver, kidney, GI, respiratory, heart and a blood system disease 2) A subject who has a past histroy of drug dependency 3) A subject who is difficult for intravenous administration (including episodes of vagal reflex syncope) 4) A subject who has the past of clinically significant drug allergy symptom and allergy to vaccine( eanaphylactic shock, severe food allergy, hives, recurrent dermatitis, drug hypersensitivity, allergy to protein preparation, vascular edema) 5) A subject who has clinically important abnormal laboratory data by a blood test or urine test at the time of screening 6) A subject who is HIV Ab, HBs Ag, or HCV Ab positive by screening examination 7) Screening or baseline Qtc is over 450 msec or QRS interval is over 120 msec by 12-lead electrocardiogram 8) Screening or baseline BP is over 140/90 mmHg or below 100/50, or HR is out of the range of 40-100 after 5 minutes rest 9) A subject who has fever(body temperature over 37 degrees Celsius) 10) A subject who participated in other clinical trials within four months and received a clinical trial drug (including a placebo) 11) A subject using prescribed drug and/or Over-The-Counter drugs within 14 days 12) The person who lost more than 400 mL blood within 12 weeks or 200 ml blood within 4 weeks(by blood donation, etc.) 13) Ineligible by other reasons judged by the investigators
研究者
相似试验
已完成
1 期
Mesenchymal Stromal Cells to Treat Steroid-refractory Graft Versus Host Disease after Bone Marrow TransplantatioGraft Versus Host DiseaseInflammatory and Immune System - Other inflammatory or immune system disordersBlood - Haematological diseasesACTRN12610000068066R.P.Herrmann20
招募中
1 期
Comparison of the efficacy of mesenchymal stem cells condition medium injection and ow level laser in the treatment of alopeciaIRCT20200127046282N27Shahid Beheshti University of Medical Sciences30
招募中
1 期
Evaluation of the safety and effectiveness of mesenchymal stem cells conditioned medium in the treatment of hair lossHair loss.Nonscarring hair loss, unspecifiedL65.9IRCT20200127046282N13Tehran University of Medical Sciences45
尚未招募
1 期
A safety study of autologous mesenchymal precursor cells (MPCs) in the management of delayed healing tibial fractures requiring secondary surgical intervention to promote fracture union.Delayed or non-union tibial fractureMusculoskeletal - FracturesACTRN12605000051640Mesoblast10
进行中（未招募）
1 期
Assessment of safety and clinical tolerability of increasing doses of the investigational medicinal product hdmASIT+TM injected under the skin of patients suffering from perennial allergic rhinitisTreatment of house dust mite induced allergic rhinoconjunctivitisMedDRA version: 20.0Level: LLTClassification code 10001728Term: Allergic rhinoconjunctivitisSystem Organ Class: 100000014962EUCTR2016-000557-13-DEASIT biotech S.A.